Gamma delta T-cell receptor target antigen (γδ TCR antigen)

Gamma delta (γδ) T-cell receptor target antigens are a distinct class of molecules recognized by γδ T cells, which function independently of the classical Major Histocompatibility Complex (MHC) (Willcox & Willcox, 2019, Nature Reviews Immunology). The most prominent group of these antigens are phosphoantigens, such as (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) and isopentenyl pyrophosphate (IPP), which are sensed by the Vγ9Vδ2 T-cell subset (Rigau et al., 2020, Science). This sensing mechanism is unique, requiring the presence of butyrophilin proteins, specifically BTN3A1 and BTN2A1, which act as molecular switches to signal the presence of intracellular phosphoantigens to the TCR (Rigau et al., 2020, Science). Beyond phosphoantigens, γδ T cells can recognize stress-induced proteins like MICA and MICB, as well as lipid antigens presented by CD1 molecules, allowing them to detect a wide array of cellular abnormalities (Luoma et al., 2013, Immunity). These antigens serve as critical signals for the identification of "stressed" cells, including those that are malignantly transformed or virally infected. In therapeutic contexts, drugs like aminobisphosphonates (e.g., zoledronic acid) are used to induce the accumulation of endogenous IPP by inhibiting the farnesyl pyrophosphate synthase enzyme (Sebestyen et al., 2020, Cell Reports). Additionally, novel monoclonal antibodies and bispecific engagers are being developed to target butyrophilins or the TCR directly to facilitate potent γδ T-cell activation against tumors (Sebestyen et al., 2020, Cell Reports). This unique recognition system makes γδ TCR target antigens highly attractive for "off-the-shelf" cancer immunotherapies due to the lack of MHC restriction and reduced risk of graft-versus-host disease.

Other names

PhosphoantigenNon-peptide antigenButyrophilin-mediated antigenγδ TCR ligandVγ9Vδ2 TCR ligand

Activation of γδ T cells through the modulation of butyrophilin proteins (e.g., BTN3A1) or the accumulation of intracellular phosphoantigens (e.g., IPP) to trigger MHC-independent cytotoxicity against target cells.